FDA Held Its First Big Psychedelics Hearing. Nobody From the Government Asked a Question.

The short answer

The link making the rounds is a promo for "THE GATEWAY" — a $20 ticketed networking event and live podcast taping that Psychedelics Today ran with SSDP and MAPS at a Copper Canyon Grill in Silver Spring, Maryland on the evening of September 14, 2026 (https://psychedelicstoday.com/2026/09/10/the-gateway-live-from-dc-after-the-fda-psychedelics-hearing/). A sensemaking session at a chain restaurant is a fine way to decompress. It is not the news.

The news is what happened earlier that day, a few minutes up the road. FDA convened a Part 15 public hearing titled "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs" at its White Oak campus, 12:30 to 4:30 p.m. ET, hybrid format. The announcement ran in the Federal Register on July 14, 2026 (91 FR 43095). FDA's event page, including the email for written submissions, is here: https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/considerations-potential-future-therapeutic-use-psychedelic-drugs-public-hearing-09142026

This was not a vote, not an advisory committee, and not a scheduling proceeding. It was FDA asking, out loud and in public, what the delivery system for an approved psychedelic should look like: who administers the drug, how patients get screened, whether a Risk Evaluation and Mitigation Strategy (REMS) is needed, and how the data get collected.

One thing you can still do: written comments are open until 11:59 p.m. ET on October 5, 2026. Everything else here is watching.

What happened in the room — and what didn't

Roughly 300 people attended in person and about 1,000 watched online, from more than 1,800 registrations. Marta Sokolowska gave FDA's opening remarks. Speakers got two minutes apiece. Psychedelic Alpha's write-up — headlined, accurately, "No questions asked" — reported that the federal panel asked nothing all afternoon: https://psychedelicalpha.com/news/no-questions-asked-fdas-psychedelics-public-hearing/

Read that however you like. A charitable reading is that a Part 15 hearing is structurally a listening exercise and the docket is where the real exchange happens. A less charitable reading is that the agency had already framed its four questions and wanted testimony, not dialogue.

The substantive disagreements were real, and they were about access versus control:

• Peter Hendricks argued that mandating psychotherapy alongside the drug would price out low-income and uninsured patients.

• Laurel Kilgour warned that "an overly zealous risk mitigation framework can undermine safety" by pushing people toward unregulated sources.

• Eddie Jacobs argued for an initial safety floor anchored to the conditions trials were actually run under.

• Amber Barnato pointed at "small, functionally unblinded trials" — more on that below.

• Kevin Sabet, opposed, attacked sample sizes and speakers' financial interests.

• Susan Taymor Sagy testified that her 21-year-old daughter died following psychedelic use.

That last one belongs in every summary of this hearing, including ours.

A summary published by UBC describes the agency's four topic areas as provider training and credentialing, promotion of patient safety, considerations for access, and best practices for data collection and standardization, and flags a potential REMS as a central access question: https://ubc.com/insights/summary-and-key-takeaways-from-fdas-september-2026-public-hearing-on-psychedelic-drugs/ We could not pull the Federal Register full text directly, so treat that topic list as secondary reporting rather than the notice's own wording.

What FDA explicitly did not ask about: scheduling status under the Controlled Substances Act. That is a separate track, noted by Foley Hoag here: https://foleyhoag.com/news-and-insights/publications/alerts-and-updates/2026/august/psychedelic-therapeutics-take-center-stage-fda-announces-public-hearing-and-finalizes-clinical/

And because FDA answered nothing: any confident claim about what the agency "will" require on psychotherapy or REMS is a guess. Including the confident ones.

The approval clock nobody voted on

The hearing has urgency for one reason: a filing is in motion.

Per Compass Pathways' Q2 2026 results (August 5, 2026), FDA granted rolling review of the COMP360 NDA in April 2026 and awarded a Commissioner's National Priority Voucher, which carries a potential one-to-two-month filing review. Modules are being submitted, completion is targeted for Q4 2026, and launch is projected for H1 2027 — explicitly pending both FDA approval and DEA rescheduling. Cash was $433.3M as of June 30, 2026: https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Second-Quarter-and-First-Half-2026-Financial-Results-and-Business-Highlights/default.aspx

Evidence tier: Phase 3 human RCTs, company-reported topline only. COMP005 (announced June 23, 2025) randomized 258 participants across 32 US sites to a single 25 mg dose or placebo; the week-6 MADRS treatment difference was −3.6 points (95% CI −5.7 to −1.5), p<0.001. COMP006 (announced February 17, 2026) randomized 581 participants across three fixed doses given three weeks apart; 25 mg beat the 1 mg comparator by −3.8 MADRS points at week 6, p<0.001, with 39% of the 25 mg arm reaching a ≥25% MADRS reduction. Six serious adverse events occurred in six participants (2%); SAE suicidal ideation was under 1%, and the single SAE of suicidal behavior occurred in the 1 mg arm.

Two caveats that do not appear in most coverage.

First, none of this has been peer-reviewed. Every figure above comes from company press releases and conference materials. We found no journal publication of either Phase 3 trial. That is not an accusation; it is the actual state of the record, and it is the single most important thing to know before you form an opinion.

Second, Compass defined "clinically meaningful" response as a ≥25% MADRS reduction. Antidepressant trials conventionally use 50%. Drug Discovery Trends walked through why that matters: https://www.drugdiscoverytrends.com/first-phase-3-psilocybin-data-clears-the-bar-for-treatment-resistant-depression-but-how-high-was-the-bar/

Psilocybin is not alone on this track. On the same day as the hearing, Definium Therapeutics (formerly MindMed, Nasdaq: DFTX) announced positive topline results from Panorama, a Phase 3 of DT120 — LSD, not psilocybin — in generalized anxiety disorder: 245 participants, HAM-A placebo-adjusted −5.1 points at week 12, p<0.0001, Cohen's d=0.64, with day-of-dosing illusion in 68% and nausea in 37%, and no suicidality signal. Pre-NDA meeting in Q4 2026, filing anticipated H1 2027: https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder

The methodology problem sitting underneath all of it

Evidence tier: peer-reviewed systematic review. Orsini et al., *JAMA Psychiatry* (published online April 15, 2026; 2026;83(7):755–769), reviewed 112 psychedelic RCTs — 78 ketamine, 17 LSD, 11 psilocybin, 11 MDMA, 2 ayahuasca, 2 DMT, 1 noribogaine. Only 33 of 112 (29.5%) assessed blinding integrity at all, even though 64 (57.1%) listed blinding as a limitation. Psilocybin, LSD and ayahuasca trials "frequently reported blinding failure values of more than 90% among participants and raters." The authors' conclusion: "Functional unblinding is pervasive among participants and raters raising concerns about the validity of efficacy findings." https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2847667

This is the obvious problem with studying a drug that announces itself. If you know whether you got 25 mg or an inert capsule — and you do — then your rating of your own mood is not blind, and neither is the clinician watching you.

A second peer-reviewed paper points the same way from a different angle. Meshkat et al., *European Psychiatry* 2026, meta-analyzed 14 RCTs and 643 participants. Pooled standardized mean differences favored treatment (depression −0.82, PTSD −0.89, anxiety −0.66), but control groups themselves showed medium-to-large within-group improvement, which the authors attribute to "non-specific trial factors (including expectancy and concurrent psychotherapy)": https://pmc.ncbi.nlm.nih.gov/articles/PMC13122533/

Neither paper says psychedelics don't work. Both say the size of the effect is harder to pin down than a press release implies. Worth noting that several authors in this literature are themselves active psychedelic researchers — which cuts in both directions and is a reason to read the disclosures rather than the headline.

What the regulated programs are actually seeing

Evidence tier: observational, peer-reviewed, uncontrolled.

Yu et al., *Frontiers in Psychiatry* (May 2026), described aggregate Oregon Psilocybin Services data for calendar year 2025: 5,935 clients and 5,375 administration sessions, with behavioral adverse events at 2.42 per 1,000 sessions (n=13) and medical adverse events at 2.79 per 1,000 sessions (n=15). Seven cases required hospital transport. Notably, 32.6% of clients came from outside Oregon. Stated motivations skewed toward general wellness (30.6%) and perspective change (27.7%) ahead of anxiety (23.8%) and depression (22.0%). The authors are blunt about limits: aggregate data only, no validated outcome measures, no longitudinal tracking, no way to distinguish repeat clients: https://pmc.ncbi.nlm.nih.gov/articles/PMC13224104/

A prospective cohort in *JAMA Network Open* (August 2026, doi:10.1001/jamanetworkopen.2026.30608) followed 346 adults at 24 of 26 licensed Oregon service centers, enrolled November 2024 through March 2026. Four participants (1.2%), all psychedelic-naive, had adverse behavioral reactions requiring medical attention; 1.6–2.3% reported harm across timepoints; participants self-reported reductions in depression, anxiety and PTSD symptoms at three months: https://pmc.ncbi.nlm.nih.gov/articles/PMC13491119/

Before anyone quotes that as proof of anything: the cohort was affluent and unrepresentative — mean age 49.5, 86.7% white, 76.6% college-educated, roughly 29% earning over $200K, and 55.8% already experienced with psychedelics — and it captured about 5% of Oregon's service users. Self-reported improvement with no control group tells you what people said, not what the mushrooms caused.

The useful signal is the safety denominator, not the efficacy claim: serious events in a supervised, screened setting appear to be rare. That says nothing about an unsupervised session with no screening.

Where this is legal today — and where it isn't

Psilocybin is Schedule I at 21 CFR §1308.11(d)(29), DEA code 7437, with psilocyn at (d)(30), code 7438: https://www.law.cornell.edu/cfr/text/21/1308.11 Nothing at the hearing touched that, and FDA did not ask for comment on it.

Oregon. Measure 109, codified at ORS 475A with rules at OAR 333-333. OHA licenses facilitators, service center operators, manufacturers, labs and worker permits; service centers opened in summer 2023, and quarterly data reporting has been mandated since January 1, 2025 under SB 303 (2023). Program page: https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx and dashboard: https://www.oregon.gov/oha/ph/preventionwellness/pages/psilocybin-data-dashboard.aspx You'll see wildly different licensed-center counts online; the *JAMA Network Open* cohort implies 26 centers held active licenses during its enrollment window, which is a sourced number rather than a blog aggregate. More at /legal-status/oregon.

New Mexico. SB 219, the Medical Psilocybin Act, was signed in April 2025 and took effect June 20, 2025, with qualifying conditions covering treatment-resistant major depression, PTSD, substance use disorders and end-of-life care. NM DOH is targeting implementation by December 31, 2026, ahead of a statutory 2027 deadline. Producer permit applications opened August 17, 2026. Patient enrollment has not opened. https://www.nmhealth.org/about/mcpp/mpp/ and /legal-status/new-mexico.

Colorado runs a licensed healing-center framework as well; we're not printing a center count here because we could not verify one from the state directly. Framework comparison: /vs/oregon-vs-colorado-psilocybin-therapy.

The federal push. Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness," signed April 18, 2026, directs National Priority Vouchers for psychedelics with Breakthrough designation, at least $50M from ARPA-H for federal–state collaboration, HHS/FDA/VA data-sharing MOUs, and instructs the Attorney General with HHS to initiate and complete scheduling review of Schedule I products that have completed Phase 3 "as quickly as practicable": https://www.presidency.ucsb.edu/documents/executive-order-14401-accelerating-medical-treatments-for-serious-mental-illness On April 24, 2026, FDA announced National Priority Vouchers for psilocybin in TRD, psilocybin in MDD and methylone in PTSD, plus IND clearance for noribogaine in alcohol use disorder, with Commissioner Marty Makary framing development as needing to be "grounded in sound science and rigorous clinical evidence": https://www.fda.gov/news-events/press-announcements/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order FDA also finalized its "Psychedelic Drugs: Considerations for Clinical Investigations" guidance in July 2026: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations

The same EO directs FDA and DEA to establish a Right to Try pathway. We found no evidence that any such pathway exists yet. If someone offers you psilocybin today under a "Right to Try" banner, that is a sales pitch, not a legal route.

PsyBear takeaways

1. The only participatory part closes October 5. Written comments to FDA are due 11:59 p.m. ET, October 5, 2026, via the address on FDA's event page (PsychedelicsHearing@fda.hhs.gov). Patients, facilitators and clinicians with real experience are exactly who the record is thin on.

2. "No questions asked" is the headline. Per Psychedelic Alpha, federal panelists asked nothing across an afternoon of testimony. Nobody outside FDA knows what the agency concluded about psychotherapy mandates or a REMS, because FDA did not say.

3. Topline is not peer review. COMP005, COMP006 and Panorama exist right now as company press releases. Real numbers, real trials, unpublished. Hold them accordingly, and be suspicious of anyone quoting a MADRS point difference with more certainty than Compass does.

4. Approval ≠ legal. Compass itself says launch depends on FDA approval and DEA rescheduling. Until both happen, psilocybin is Schedule I everywhere in the US outside licensed state programs and authorized research.

5. A prescription pad is not arriving this year, and the gap is the dangerous part. Kilgour's point at the hearing — that over-restrictive rules push people to unregulated sources — describes the next 12 months for a lot of readers. If that's you, the whole job is screening, setting and a sober sitter: /guides/safe-trip, /guides/trip-preparation, /guides/trip-sitter.

6. Interactions are still the thing most likely to hurt you. Standard research exclusions (Johnson, Richards & Griffiths, *J Psychopharmacol* 2008) rule out personal or first/second-degree family history of schizophrenia, psychotic disorders or bipolar I/II, severe cardiovascular disease, resting BP over 140/90, and pregnancy. The same paper notes TCAs and lithium potentiate effects, chronic SSRIs and MAOIs reduce sensitivity, and flags St. John's Wort and 5-HTP: https://files.csp.org/Psilocybin/HopkinsHallucinogenSafety2008.pdf On lithium specifically, Nayak, Gukasyan et al. (*Pharmacopsychiatry* 2021) mined 62 online reports of lithium plus a classic psychedelic and found 47% involved seizures — anecdotal report-mining, not a controlled study, and the authors call their own conclusion provisional. That is still more than enough reason not to find out yourself: /guides/psilocybin-and-lithium and /guides/psilocybin-drug-interactions.

7. One open-label trial is not permission. Goodwin et al. (*Neuropsychopharmacology* 2023) gave 25 mg COMP360 alongside a continuing SSRI in TRD and reported it tolerated — open-label, fixed-dose, three-week follow-up, inside a monitored protocol. It is not evidence that combining psilocybin with your antidepressant at home is safe: /guides/psilocybin-and-ssris.

Key Takeaways

On September 14, 2026, FDA held a Part 15 public hearing on the potential future therapeutic use of psychedelic drugs at its White Oak campus — roughly 80 speakers, about 300 people in the room and 1,000 online, federal listeners from FDA, NIDA, VA, SAMHSA and ARPA-H, and, per Psychedelic Alpha, zero questions from the federal panel. The written docket stays open until 11:59 p.m. ET on October 5, 2026, which is the only part of this an ordinary person can actually participate in. It matters because Compass Pathways is targeting Q4 2026 to complete a rolling NDA for synthetic psilocybin in treatment-resistant depression, which would put a classic psychedelic in front of an FDA approval decision for the first time. It also matters because none of the Phase 3 results driving that filing have been peer-reviewed, and a July 2026 JAMA Psychiatry systematic review of 112 psychedelic RCTs found functional unblinding is pervasive. Psilocybin remains Schedule I federally. Approval alone would not change that — DEA rescheduling is a separate step.

FAQ

What was the FDA psychedelics hearing on September 14, 2026?

A Part 15 public hearing titled "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," held 12:30–4:30 p.m. ET at FDA's White Oak campus in Silver Spring, Maryland, in hybrid format, and announced in the Federal Register on July 14, 2026 (91 FR 43095). It focused on how an approved psychedelic medicine would be delivered — provider training, patient safety, access and data collection — not on scheduling.

Can I still submit a comment to FDA?

Written comments were open until 11:59 p.m. ET on October 5, 2026. FDA listed PsychedelicsHearing@fda.hhs.gov on its event page as the contact for the hearing.

Did FDA say what it will require for psilocybin therapy?

No. Roughly 80 speakers testified for two minutes each in front of federal listeners from FDA, NIDA, VA, SAMHSA and ARPA-H, and per Psychedelic Alpha no federal panelist asked a single question. A potential REMS was flagged as a key access consideration, but any claim about what FDA will actually require on psychotherapy or risk mitigation is speculation.

Is psilocybin close to FDA approval?

Compass Pathways has a rolling NDA under review for COMP360 synthetic psilocybin in treatment-resistant depression, with submission completion targeted for Q4 2026 and launch projected for H1 2027 — explicitly contingent on both FDA approval and DEA rescheduling. Its two Phase 3 trials, COMP005 and COMP006, hit their primary endpoints, but neither has been published in a peer-reviewed journal.

How strong is the evidence that psilocybin treats depression?

Weaker than headlines suggest. Compass reported a week-6 MADRS difference of −3.6 points in COMP005 and −3.8 points in COMP006 against a 1 mg comparator, using a ≥25% MADRS reduction as its response threshold where antidepressant trials conventionally use 50%. A July 2026 JAMA Psychiatry systematic review of 112 psychedelic RCTs found that functional unblinding is pervasive among participants and raters, raising concerns about the validity of efficacy findings.

Where is psilocybin legal in the US right now?

Psilocybin is Schedule I federally at 21 CFR §1308.11(d)(29). Oregon operates a licensed program under ORS 475A with rules at OAR 333-333, and Colorado licenses healing centers. New Mexico's Medical Psilocybin Act took effect June 20, 2025 and opened producer permit applications on August 17, 2026, but patient enrollment has not opened. An FDA approval would not by itself make psilocybin federally legal — DEA rescheduling is a separate step.

Related resources

• Psilocybin Therapy Guide
• Safe Trip Guide
• Psilocybin Drug Interactions
• Oregon Legal Status
• New Mexico Legal Status
• Treatment-Resistant Depression